Dr. Nuermberger is an Associate Professor of Medicine and International Health at Johns Hopkins University. His primary research interest is the experimental chemotherapy of TB. The work uses well-validated murine models of active TB and latent TB infection to evaluate the efficacy of promising new antimicrobials. A major goal is to identify new agents that can be combined with existing drugs to shorten the duration of TB therapy or allow more intermittent drug administration.
Conflict of Interest: I have research grants and contracts from Janssen, TB Alliance and the Gates Medical Research Institute in addition to NIH.